KOATE-DVI 250 IU I.V. VIAL 5 ML

Koate-DVI is indicated for the treatment of classical hemophilia (hemophilia A) in which there is a demonstrated deficiency of activity of the plasma clotting factor Factor VIII. Koate-DVI provides a means of temporarily replacing the missing clotting factor in order to control or prevent bleeding episodes or in order to perform emergency and elective surgery on individuals with hemophilia. Koate-DVI contains naturally occurring von Willebrand factor which is co-purified as part of the manufacturing process. Koate-DVI is a human plasma-derived factor VIII replacement therapy that is indicated to treat patients with hemophilia A for over 10 years. Koate-DVI is proven to rapidly increase levels of factor VIII and to stop bleeding episodes.1 Koate-DVI has a low risk for side effects is manufactured with dedicated steps to inactivate or remove viruses.